Business Context and Reporting Period
This Form 8-K is a current report filed by Obalon Therapeutics, Inc. (not Vyome Holdings, Inc.) on December 1, 2017, regarding an event that occurred on November 28, 2017. The registrant is a Delaware corporation and an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation adjustments.
Material Changes
The primary material change reported is an increase in the annual base salary for William Plovanic, the Company's Chief Financial Officer. The Compensation Committee approved raising his salary from $315,000 to $400,000, effective January 1, 2018.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, risks, contingencies, or unusual items beyond the specific compensation adjustment noted above.
Key Facts for Investor Verification
- Verify the effective date of the CFO salary increase (January 1, 2018).
- Confirm the new annual base salary amount ($400,000) versus the prior amount ($315,000).
- Note that this filing does not contain financial performance data for the period.